SFOSF (Shanghai Fosun Pharmaceutical (Group) Co) Long-Term Capital Lease Obligation : $363 Mil (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co Long-Term Capital Lease Obligation?

Shanghai Fosun Pharmaceutical (Group) Co's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was $363 Mil.

Shanghai Fosun Pharmaceutical (Group) Co's quarterly Long-Term Capital Lease Obligation increased from Sep. 2024 ($313 Mil) to Dec. 2024 ($349 Mil) and increased from Dec. 2024 ($349 Mil) to Mar. 2025 ($363 Mil).

Shanghai Fosun Pharmaceutical (Group) Co's annual Long-Term Capital Lease Obligation increased from Dec. 2022 ($107 Mil) to Dec. 2023 ($287 Mil) and increased from Dec. 2023 ($287 Mil) to Dec. 2024 ($349 Mil).

Shanghai Fosun Pharmaceutical (Group) Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Long-Term Capital Lease Obligation Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

95.93

101.80

106.86

287.05

349.14

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															278.73	269.88	313.35	349.14	362.72

Shanghai Fosun Pharmaceutical (Group) Co (OTCPK:SFOSF) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Shanghai Fosun Pharmaceutical (Group) Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Fosun Pharmaceutical (Group) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (OTCPK:SFOSF) » Definitions » Long-Term Capital Lease Obligation

Traded in Other Exchanges

02196:Hong Kong 08HH:Germany 600196:China

Address

No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233

Website

https://www.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.